Well the title is MSB trading, so I feel vindicated in making...

Well the title is MSB trading, so I feel vindicated in making this comparison.

Holding this stock is like holding an upside out of the money call option. There is the potential for an announcement to send the stock price higher at any time, but in the mean time, you just watch value decay away. I hope Dr Itescu manages to win over those collaborators and regulators very soon and this call option might go back to $3.00 rather than zero.

Been what nearly a month now since possibility of COVID trials announced? I've been distracted with other stocks in my portfolio - its times like this when diversification merits go out the window and you cannot keep track of everything. Lots of great information on here. Thanks guys. Why the stock has been so punished since the early March announcement I don't know. It seems to me one announcement could send this stock skyward.

I know many of you are in this stock for other reasons (as was I) but it would be a terrible shame if Remestemcell-L was overlooked as an aid to patients with acute respiratory distress syndrome (ARDS) from coronavirus. It clearly has application, so much more than much of the other speculative crap out there - and believe me I have researched the potential to death. From reading many of the posts on here I feel it has better potential than both Gilead and Moderna (the main likely contenders in the treatment race).

Whilst its more general future use and other products were the reason for my original investment, I feel in the present environment this could be make or break for a company unlikely before this event to have been cash positive before 2022 -- a comment which will rankle many of you I am sure, but this crisis has changed the cash prospects for most collaborative bio-techs.